Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis

被引:17
|
作者
Forbes, K
Gillette, K
Kelley, LA
Sehgal, I
机构
[1] Louisiana State Univ, Sch Vet Med Comparat Biomed Sci, Baton Rouge, LA 70809 USA
[2] N Dakota State Univ, Ctr Protease Res, Fargo, ND 58105 USA
[3] N Dakota State Univ, USDA Lab, Fargo, ND 58105 USA
关键词
urokinase plasminogen activator receptor; prostate cancer; secondary metastasis; motility;
D O I
10.1007/s00345-003-0395-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To understand alterations to the urokinase system that may occur in progressively metastatic prostate cancer cells, we assessed urokinase plasminogen activator receptor (uPAR) expression, in vitro motility towards vitronectin, urokinase plasminogen activator (uPA)-induced growth and growth factor regulation of uPAR expression in three cell lines-PC-3 and two derivatives from secondary metastases, PC-3M and PC-3MM2. DU-145 and Tsu-Pr1 cells were included for comparative purposes. uPAR expression increases with metastatic passage in these cell lines and accompanies increased growth and motility responses in the presence of uPA. Growth factors TGFbeta1 and IGF-1 induce uPAR in all three prostate cancer lines; however, PC-3M and PC-3MM2 cells also respond to bFGF. Of the cell lines tested, PC-3MM2 most uniformly respond to added TGFbeta1, IGF-1 and bFGF. These results show that in two progressive derivatives from repeated metastasis of PC-3 cells, constitutive and growth factor-induced uPAR expression is enhanced. This increased uPAR facilitates the properties of growth and motility.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 50 条
  • [11] Increased Urokinase-Type Plasminogen Activator Receptor and Epidermal Growth Factor Receptor in Serum of Patients With Prostate Cancer
    Milanese, Giulio
    Dellabella, Marco
    Fazioli, Francesca
    Pierpaoli, Elisa
    Polito, Massimo
    Siednius, Nicolai
    Montironi, Rodolfo
    Blasi, Francesco
    Muzzonigro, Giovanni
    JOURNAL OF UROLOGY, 2009, 181 (03): : 1393 - 1400
  • [12] Urokinase plasminogen activator receptor in breast cancer
    Brunner, N
    HolstHansen, C
    Pedersen, AN
    Pyke, C
    HoyerHansen, G
    Foekens, J
    Stephens, RW
    BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 201 - 207
  • [13] Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA
    Mohanam, S
    Chintala, SK
    Mohan, PM
    Sawaya, R
    Lagos, GK
    Gokaslan, ZL
    Kouraklis, GP
    Rao, JS
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 13 (06) : 1285 - 1290
  • [14] Urokinase plasminogen activator receptor (uPAR) as a novel biomarker in prostate cancer.
    Lippert, Solvej
    Berg, Kasper Drimer
    Iversen, Peter
    Hoyer-Hansen, Gunilla
    Christensen, Ib Jarle
    Brasso, Klaus
    Roder, M. Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [15] The role of urokinase plasminogen activator receptor in HNcSCC progression and metastasis
    Minaei, Elahe
    Mueller, Simon A.
    Thind, Amarinder Singh
    Ashford, Bruce
    Perry, Jay
    Clark, Jonathan
    Gupta, Ruta
    Ranson, Marie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 34 - 34
  • [16] Imaging Active Urokinase Plasminogen Activator in Prostate Cancer
    LeBeau, Aaron M.
    Sevillano, Natalia
    Markham, Kate
    Winter, Michael B.
    Murphy, Stephanie T.
    Hostetter, Daniel R.
    West, James
    Lowman, Henry
    Craik, Charles S.
    VanBrocklin, Henry F.
    CANCER RESEARCH, 2015, 75 (07) : 1225 - 1235
  • [17] Tissue urokinase-type plasminogen activator receptor levels in breast cancer
    Gong, SJ
    Rha, SY
    Chung, HC
    Yoo, NC
    Roh, JK
    Yang, WI
    Lee, KS
    Min, JS
    Kim, BS
    Chung, HC
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2000, 6 (03) : 301 - 305
  • [18] Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer
    Kristensen, Gitte
    Berg, Kasper Drimer
    Lippert, Solvej
    Christensen, Ib Jarle
    Brasso, Klaus
    Hoyer-Hansen, Gunilla
    Roder, Martin Andreas
    JOURNAL OF CLINICAL PATHOLOGY, 2017, 70 (12) : 1063 - 1068
  • [19] Elevated plasma levels of urokinase plasminogen activator and its receptor are strongly associated with prostate cancer presence and progression
    Sadeghi, F
    Shariat, S
    Kattan, MW
    Andrews, B
    Wheeler, TM
    Slawin, KM
    JOURNAL OF UROLOGY, 2003, 169 (04): : 161 - 161
  • [20] Significance of Urokinase plasminogen activator-system in disseminated prostate cancer cells
    Thomas, C.
    Melchior, S.
    Wiesner, C.
    Brenner, W.
    Thueroff, J. W-
    UROLOGE, 2007, 46 (09): : 1286 - 1287